Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
September 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
September 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Multiple Myeloma
Multiple Myeloma
,
Conference Highlights ASCO
New CAR T-Cell Therapy Produces Durable Responses in Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
Read More
FDA Approvals
,
Multiple Myeloma
,
Conference Highlights ASCO
FDA Approves Darzalex Faspro plus Pomalyst and Dexamethasone for Multiple Myeloma
Read More
FDA Approvals
,
Multiple Myeloma
,
Select Drug Profiles
FDA Approved Pepaxto for Relapsed or Refractory Multiple Myeloma
Read More
FDA Approvals
,
Multiple Myeloma
,
Select Drug Profiles
FDA Approved Abecma, First CAR T-Cell Therapy for Multiple Myeloma
Read More
FDA Approvals
,
Multiple Myeloma
Xpovio Approved for Patients with Relapsed or Refractory Multiple Myeloma
Read More
Multiple Myeloma
Belantamab Induces Deep Responses in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
Read More
Multiple Myeloma
Bispecific Antibodies in Phase 1 Studies Show Promising Efficacy in Heavily Pretreated Patients with Multiple Myeloma
Wayne Kuznar
Read More
Multiple Myeloma
CAR T-Cell Therapy Shows Deep, Durable Responses in Relapsed or Refractory Multiple Myeloma
Chase Doyle
Read More
Multiple Myeloma
Novel BCMA-Directed CAR T-Cell Therapy Had Excellent Responses in Heavily Pretreated Patients with Multiple Myeloma
Phoebe Starr
Read More
Multiple Myeloma
Dual-Targeted CAR T-Cell Therapy Leads to Very High Response Rates in Relapsed or Refractory Multiple Myeloma
Phoebe Starr
Read More
1
2
3
4
Page 1 of 6
Results 1 - 10 of 52